AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) entered definitive agreements for a registered direct offering of 7,519,351 common shares (or equivalents) at $0.325 per share, for expected gross proceeds of about $2.4 million before fees.
Concurrent with this, AIM will privately issue Series I warrants to purchase up to 15,038,702 shares at $0.325, exercisable for five years subject to stockholder approval. Closing is expected around May 21, 2026. According to AIM ImmunoTech, net proceeds will fund clinical drug supply manufacturing, planned Phase 3 trial activities, and working capital.
AI-generated analysis. Not financial advice.
Positive
- Approximately $2.4 million gross proceeds from equity financing
- Cash earmarked for clinical drug supply and Phase 3 activities
- Additional capital potential from 15,038,702 Series I warrants
- Five-year warrant term may support longer-term funding flexibility
Negative
- New 7,519,351 shares create equity dilution for existing holders
- Exercise of 15,038,702 warrants could further increase share count
- Warrant exercisability contingent on stockholder approval
- Closing remains subject to customary closing conditions
Key Figures
Market Reality Check
Peers on Argus
AIM was up 5.69% ahead of this offering news, while momentum scanner flagged peers like HCWB, ALZN, and ADIL with strong upside moves. Scanner still characterizes this as a stock-specific move rather than a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 19 | Balance sheet update | Positive | +0.7% | Reported swing to positive stockholder equity and note maturity extension. |
| May 14 | KOL data spotlight | Positive | -4.8% | Showcased Ampligen pancreatic cancer data and development strategy to investors. |
| May 08 | Warrant exercise deal | Negative | -39.7% | Inducement for warrant exercises raising about $4.2M with new replacement warrants. |
| May 07 | Phase 2 results | Positive | +16.4% | Reported 50% ORR and durable responses in recurrent ovarian cancer trial. |
| Apr 13 | Annual filing update | Negative | +9.0% | Disclosed going concern emphasis with update on DURIPANC trial progress. |
Recent financings and warrant transactions (e.g., early May offerings) have often pressured AIM’s share price, while strong clinical updates have tended to see positive or mixed reactions.
Over the last few months, AIM balanced capital-raising with advancing oncology programs. A Feb–Mar 2026 rights offering and early May warrant exercises raised several million dollars but were followed by sharp drawdowns, notably a -39.66% move on the May 8 inducement deal. In contrast, positive clinical data in ovarian and pancreatic cancer around May 7 and earlier filings have produced mixed-to-positive price reactions. Today’s registered direct/pipe financing continues that pattern of frequent equity-linked raises alongside late-stage clinical ambitions.
Regulatory & Risk Context
AIM has an effective Form S-3/A shelf (effective July 3, 2025) authorizing up to $100 million of various securities. Today’s registered direct offering is a takedown from that shelf, illustrating active use of this capital markets capacity and the potential for further equity or equity-linked issuance over time.
Market Pulse Summary
This announcement details a registered direct offering and concurrent private placement raising about $2.4 million at $0.325 per share, plus 15,038,702 Series I warrants. Proceeds are earmarked for clinical drug supply, planned Phase 3 trial work, and working capital. It taps AIM’s effective Form S-3 shelf, part of a broader pattern of rights offerings and warrant deals. Investors may track future capital raises, trial milestones, and how added dilution interacts with AIM’s low share price and past going-concern disclosures.
Key Terms
registered direct offering financial
private placement financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
section 4(a)(2) regulatory
regulation d regulatory
placement agent financial
AI-generated analysis. Not financial advice.
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value
Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.
The offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offering for (i) the manufacture of clinical drug supply, (ii) the Company’s planned Phase 3 clinical trial activities, and (iii) working capital purposes.
The Common Stock (or common stock equivalents in lieu thereof) are being offered and sold pursuant to a prospectus supplement to be filed with the Securities and Exchange Commission (“SEC”) in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-286319), which was declared effective by the Securities and Exchange Commission (“SEC”) on July 3, 2025. The offering is being made only by means of a prospectus supplement and accompanying prospectus which are a part of the effective registration statement. The warrants will be issued in a concurrent private placement. A prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying prospectus may be obtained from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, NY 10019, by phone at (212) 409-2000, or by email at prospectus@ladenburg.com. The private placement of the Series I Warrants and the shares underlying the warrants offered to the institutional investor(s) will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder. Accordingly, the securities issued in the concurrent private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 to the extent available. Forward-looking statements include all statements other than statements of historical fact and may be identified by words such as “believes,” “expects,” “intends,” “may,” “will,” “plans,” “potential,” “anticipates,” “estimates,” “continues,” “could,” “should” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include, without limitation, statements regarding the offering, the expected gross proceeds and anticipated closing of the offering, the intended use of proceeds, the issuance and terms of the Series I Warrants, anticipated milestones, the timing of commencement, enrollment, completion and results of clinical trials, the Company’s clinical and operational priorities, intellectual property expansion, regulatory progress and the timing and receipt of government approvals, if at all.
These forward-looking statements are based on the Company’s current expectations, estimates, forecasts and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks related to the satisfaction of closing conditions, market conditions, the availability and sufficiency of funding and clinical drug supply, the Company’s ability to conduct and complete planned clinical trials, the timing and results of preclinical studies and clinical trials, whether preliminary or preclinical results will be predictive of future clinical trial results or results in humans, the need for and receipt of regulatory approvals, changes in priorities at institutions sponsoring or conducting trials, the Company’s ability to protect and enforce its intellectual property rights, risks associated with potential foreign operations and other risks described in the Company’s filings with the SEC.
The Company is in various stages of determining whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers and immune-deficiency disorders, and significant additional testing and trials will be required to determine whether Ampligen® will be effective for these conditions. No assurance can be given that any current or planned clinical trials will be initiated, completed, successful or yield favorable or useful data, that preliminary studies will prove accurate or that future studies will not result in findings that differ from those previously reported by the Company. For a further discussion of risks and uncertainties, please review the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, including any prospectus supplement filed in connection with the offering and the documents incorporated by reference therein. These filings are available at www.sec.gov and www.aimimmuno.com. The information on the Company’s website is not incorporated by reference into this press release and is included for reference purposes only. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com
